HOME >> BIOLOGY >> NEWS
Emory scientists find new prostate cancer suppressor gene

ATLANTA--A gene named ATBF1 may contribute to the development of prostate cancer through acquired mutations and/or loss of expression, according to research at Emory University School of Medicine and its Winship Cancer Institute. The findings were published in the online edition of Nature Genetics on March 6. The Emory research team was led by Jin-Tang Dong, PhD, associate professor in the Winship Cancer Institute. Lead author was postdoctoral fellow Xiaodong Sun, PhD.

Although previous research has suggested that a section of chromosome 16 harbors a tumor suppressor gene in several types of human cancers, the particular gene responsible has not previously been identified. By studying the genes within the section of chromosome 16, the Emory scientists found that ATBF1 was a strong candidate for an important tumor suppressor gene because its function is frequently lost in prostate cancer through gene mutations and/or loss of expression. In addition, ATBF1 was found to inhibit cell growth in culture dishes. A tumor suppressor gene is a gene whose loss of function contributes to the development of cancer.

ATBF1 is a transcription factor (regulator of gene expression) that functions to regulate the expression of other genes. If its function is impaired by mutations or loss of expression, a cell could lose the control of cancer genes. The Myb oncogene, for example, is normally inhibited by ATBF1, but it can be activated if ATBF1 is lost.

"Sporadic cancers often are the result of multiple genetic alterations that accumulate over time," said Dr. Dong, "but only a small number of genes have been shown to undergo these frequent mutations. Because ATBF1 inhibits cell proliferation, frequent acquired mutations that inhibit the gene, such as the ones we found, could lead to a lack of growth control in prostate cancer. Because gene deletion in chromosome 16 is common in many types of cancer, including lung, head and neck, nasopharynx, stomach, breast, and
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
22-Mar-2005


Page: 1 2

Related biology news :

1. New genetic test developed at Emory advances detection and diagnosis of muscular dystrophy
2. Emory scientists develop new map of genetic variation in human genome
3. Hormones may affect how brain listens, Emory study finds
4. Emory scientists discover unique binding method for essential cellular protein ubiquitin
5. Blood conservation strategies take center stage at Emory University Hospital forum
6. NIH awards Georgia Tech/Emory $11.5 M for nano cardiology research
7. Emory scientist finds different paths lead to similar cognitive abilities
8. Emory study finds monarch health tied to migration
9. Emory researchers find more evidence for childrens growth spurts, pain
10. Emory biochemist writes lead essay describing Nobel Prize research on ubiquitin protein
11. Emory study details dolphin brain evolution for the first time

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2019)... ... May 20, 2019 , ... The ASGCT Clinical Trials Finder is ... throughout the United States. Data curated daily from ClinicalTrials.gov ensures the most up-to-date and ... who volunteered to assist in the development of the ASGCT Clinical Trials Finder ...
(Date:5/15/2019)... , ... May 15, 2019 , ... ... process of histology wherein tissues are cut into ultra-thin two-dimensional slices, placed on ... in the context of the brain is that the brain is a highly ...
(Date:5/8/2019)... Texas (PRWEB) , ... May ... ... Gary Hutchinson has been accepted into Forbes Technology Council, an invitation-only community ... Inc. Verified Company, is a full-service biopharmaceutical cold chain engineering firm that ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... Calif. (PRWEB) , ... April 09, 2019 , ... ... services firm focused on increasing the capacity of life sciences organizations to accelerate ... Cloud Assurance platform in the past 12 months. , USDM’s ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific ... CARB-X has proceeded with a second stage of funding for Specific’s Reveal™ rapid ... is on top of the $1.7 million already awarded by CARB-X. The additional ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... collection, and analysis to a team of researchers at Nnamdi Azikiwe University in ... Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences and ...
Breaking Biology Technology:
Cached News: